ATE212664T1 - Verfahren zum spezifischen schneiden von rna- strängen - Google Patents

Verfahren zum spezifischen schneiden von rna- strängen

Info

Publication number
ATE212664T1
ATE212664T1 AT94901178T AT94901178T ATE212664T1 AT E212664 T1 ATE212664 T1 AT E212664T1 AT 94901178 T AT94901178 T AT 94901178T AT 94901178 T AT94901178 T AT 94901178T AT E212664 T1 ATE212664 T1 AT E212664T1
Authority
AT
Austria
Prior art keywords
rna strands
cutting rna
specifically cutting
specifically
activator
Prior art date
Application number
AT94901178T
Other languages
English (en)
Inventor
Paul Torrence
Robert Silverman
Ratan Maitra
Krystyna Lesiak
Original Assignee
Us Gov Health & Human Serv
Cleveland Clinic Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Cleveland Clinic Res Inst filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE212664T1 publication Critical patent/ATE212664T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94901178T 1992-10-21 1993-10-20 Verfahren zum spezifischen schneiden von rna- strängen ATE212664T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96566692A 1992-10-21 1992-10-21
US08/123,449 US5583032A (en) 1992-10-21 1993-09-17 Method of cleaving specific strands of RNA
PCT/US1993/010103 WO1994009129A2 (en) 1992-10-21 1993-10-20 Method of cleaving specific strands of rna

Publications (1)

Publication Number Publication Date
ATE212664T1 true ATE212664T1 (de) 2002-02-15

Family

ID=26821570

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94901178T ATE212664T1 (de) 1992-10-21 1993-10-20 Verfahren zum spezifischen schneiden von rna- strängen

Country Status (9)

Country Link
US (3) US5583032A (de)
EP (1) EP0666910B1 (de)
JP (1) JP3529135B2 (de)
AT (1) ATE212664T1 (de)
AU (1) AU669250B2 (de)
CA (1) CA2147282A1 (de)
DE (1) DE69331524T2 (de)
HK (1) HK1013103A1 (de)
WO (1) WO1994009129A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202225B1 (en) * 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
US20020123476A1 (en) * 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
AU730154B2 (en) 1995-10-27 2001-03-01 Elliot R. Ramberg Methods and compositions for detection of specific nucleotide sequences
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
JP2000506384A (ja) * 1996-02-15 2000-05-30 ナショナル インスティチューツ オブ ヘルス ＲＮａｓｅ Ｌ アクチベーター及びＲＳＶ感染の治療に有効なアンチセンスオリゴヌクレオチド
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
DE19631918A1 (de) * 1996-08-07 1998-02-12 Deutsches Krebsforsch Steigerung der Wirkung von Anti-Sinn-RNA in Zellen
US6468983B2 (en) * 1997-04-21 2002-10-22 The Cleveland Clinic Foundation RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
US20030165888A1 (en) * 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6518017B1 (en) 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
GB2335034B (en) * 1998-03-03 2003-08-20 Brax Genomics Ltd Screening for functional antisense agents
US6949338B2 (en) * 1998-08-18 2005-09-27 Dermtech International Methods and kits for obtaining and analyzing skin samples for the detection of nucleic acids
AU5703499A (en) * 1998-09-04 2000-03-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Peptide nucleic acid-oligoadenylate chimeric molecules
US6686148B1 (en) * 1999-03-01 2004-02-03 Nuvelo, Inc. Methods for targeting RNA molecules
AU777499B2 (en) * 1999-04-08 2004-10-21 Gen-Probe Incorporated Antisense oligonucleotides comprising universal and/or degenerate bases
US6677445B1 (en) 1999-08-27 2004-01-13 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
US8017742B2 (en) * 1999-11-10 2011-09-13 Japan Science And Technology Agency Gene carrier
US6806361B1 (en) * 2000-03-17 2004-10-19 Affymetrix, Inc. Methods of enhancing functional performance of nucleic acid arrays
AU2002346008A1 (en) * 2001-06-28 2003-03-03 Dermtech International Method for detection of melanoma
DE10133858A1 (de) * 2001-07-12 2003-02-06 Aventis Pharma Gmbh Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
US20030171315A1 (en) * 2001-07-18 2003-09-11 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for therapeutic purposes
AU2003287502B2 (en) 2002-11-05 2010-12-09 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
EP1675454A4 (de) * 2003-08-19 2007-03-21 22Nd Century Ltd Llc Tabakprodukte mit verminderter exposition
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006119466A2 (en) * 2005-05-04 2006-11-09 Immunotrex Corporation Methods for microorganism detection and identification
EP1893043A4 (de) 2005-05-11 2013-07-31 Vector Tobacco Inc Tabakprodukte mit vermindertem gesundheitsrisiko und verfahren zu ihrer herstellung
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
JP2009543868A (ja) 2006-07-17 2009-12-10 クインテセンス バイオサイエンシーズ インコーポレーティッド 癌治療に関する方法および組成物
US9102948B2 (en) 2006-11-17 2015-08-11 22Nd Century Limited, Llc Regulating alkaloids
US20110213006A1 (en) * 2007-04-20 2011-09-01 Immunotrex Corporation Compositions and Methods for Treatment of Uncontrolled Cell Growth
EP2152911A4 (de) * 2007-05-04 2010-05-19 Dermtech Int Melanomdiagnose mittels nukleinsäureanalyse
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
EP2242854A4 (de) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc Sirna-verbindungen und verfahren zur verwendung davon
ES2584325T3 (es) 2008-05-08 2016-09-27 Monsanto Do Brasil Ltda Genes y procedimientos para incrementar la resistencia a enfermedades en plantas
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
WO2010025341A2 (en) * 2008-08-28 2010-03-04 Dermtech International Determining age ranges of skin samples
JP2012504423A (ja) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ，インコーポレーテッド 治療用リボヌクレアーゼ
EP3752645A4 (de) 2018-02-14 2022-04-13 Dermtech, Inc. Neue gen-klassifikatoren und deren verwendung bei nicht-melanom-hautkrebs
WO2019209975A1 (en) * 2018-04-24 2019-10-31 The Scripps Research Institute Small molecule targeted recruitment of a nuclease to rna
WO2020198229A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567892B1 (fr) * 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons

Also Published As

Publication number Publication date
US6271369B1 (en) 2001-08-07
EP0666910A1 (de) 1995-08-16
AU5585894A (en) 1994-05-09
EP0666910B1 (de) 2002-01-30
DE69331524T2 (de) 2002-09-19
CA2147282A1 (en) 1994-04-28
AU669250B2 (en) 1996-05-30
JP3529135B2 (ja) 2004-05-24
HK1013103A1 (en) 1999-08-13
JPH08502408A (ja) 1996-03-19
US5583032A (en) 1996-12-10
US5677289A (en) 1997-10-14
DE69331524D1 (de) 2002-03-14
WO1994009129A2 (en) 1994-04-28
WO1994009129A3 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
ATE212664T1 (de) Verfahren zum spezifischen schneiden von rna- strängen
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
ATE151467T1 (de) Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
DE69840748D1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
DK0698092T3 (da) Antisenseoligonukleotider, der bekæmper uregelmæssig splejsning,og fremgangsmåder til anvendelse deraf
JPH03123485A (ja) 特異的ｒｎａ配列を切断するｒｎａ触媒
DE69720473D1 (de) Verfahren zur reinigung von nukleinsäuren
DE69818304D1 (de) Verfahren zur reduktion von oxiranyl-epothilonen zu olefinischen epothilonen
HU9303023D0 (en) Peptide nucleicadis and method for producing them
DE69736598D1 (de) Ribonukleaseresistente rna präparation und seine verwendung
FI951612A0 (fi) Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
ATE317432T1 (de) Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
ES2110604T3 (es) Metodo de secuenciacion de adn.
DE69125374D1 (en) Endonukleasen
DE69620906D1 (de) Antisense-oligonukleotidmodulation der raf-genexpression
ATE353973T1 (de) Die verwendung der 3'-wesentlichen bearbeitungswirksamkeit von dns-polymerase
ATE174065T1 (de) Simultane sequenzierung von nukleinsäuren
DE69936532D1 (de) Verfahren zum quantitativen nachweis von nukleinsäuren
ATE419341T1 (de) Verfahren zur reduzierung der rna-konzentration in einer mischung biologischen materials unter verwendung von diatomeen-erde
DE69636835D1 (de) Verfahren zur verwendung der nukleotid-integrase zur spaltung von dna und zum einbau von nukleinsäuren
BG101620A (en) Dna purification by the formation of a triple spiral with immobilized oligonucleotide
ATE294186T1 (de) Verfahren zur herstellung von nukleotiden oder oligonukleotiden phosphoramitiden
FI953363A0 (fi) Dimeeriblokkien synteesi ja niiden käyttö oligonukleotidien kokoamisessa
ATE212382T1 (de) Verfahren zur sequenzierung durch oligomerhybridisierung
Yurchenko et al. Cleavage of Leishmania Mini-exon Sequence by Oligonucleotides Conjugated to a Dimidazole Construction

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee